Avantax Advisory Services Inc. Invests $264,000 in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Avantax Advisory Services Inc. purchased a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,140 shares of the specialty pharmaceutical company's stock, valued at approximately $264,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in JAZZ. Great Lakes Advisors LLC bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $4,488,000. EverSource Wealth Advisors LLC grew its holdings in Jazz Pharmaceuticals by 96.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 620 shares of the specialty pharmaceutical company's stock worth $76,000 after acquiring an additional 305 shares during the last quarter. HighTower Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 27.0% in the fourth quarter. HighTower Advisors LLC now owns 9,648 shares of the specialty pharmaceutical company's stock valued at $1,188,000 after purchasing an additional 2,054 shares in the last quarter. Isthmus Partners LLC raised its position in shares of Jazz Pharmaceuticals by 4.9% during the fourth quarter. Isthmus Partners LLC now owns 3,359 shares of the specialty pharmaceutical company's stock worth $414,000 after acquiring an additional 157 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Jazz Pharmaceuticals by 123.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,578 shares of the specialty pharmaceutical company's stock worth $3,273,000 after purchasing an additional 14,679 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on JAZZ shares. Barclays reiterated an "overweight" rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their target price for the stock from $145.00 to $179.00 in a research note on Friday, March 7th. JPMorgan Chase & Co. raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Needham & Company LLC restated a "buy" rating and issued a $210.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. Finally, Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $187.71.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the completion of the sale, the chief executive officer now owns 439,744 shares in the company, valued at approximately $53,785,088.64. This trade represents a 0.34 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the sale, the chief accounting officer now owns 8,237 shares of the company's stock, valued at approximately $1,189,587.54. The trade was a 36.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,736 shares of company stock valued at $4,022,825. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ traded down $3.48 during trading hours on Friday, reaching $122.92. 1,709,286 shares of the company were exchanged, compared to its average volume of 735,368. The business's 50 day simple moving average is $132.30 and its 200-day simple moving average is $122.54. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $148.06. The stock has a market capitalization of $7.47 billion, a P/E ratio of 17.31, a P/E/G ratio of 1.04 and a beta of 0.44.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.